综合数字健康项目对糖尿病和糖尿病前期患者12个月HbA1c和体重的影响:一项随机对照试验
该随机对照试验在新西兰初级保健机构中比较数字健康项目(BetaMe/Melon)与常规护理对2型糖尿病和糖尿病前期患者血糖控制的效果。
要点
- 数字健康项目未改善12个月HbA1c和体重结局。
- 糖尿病组HbA1c平均差异-0.9 mmol/mol(95%CI -2.9, 1.1)。
- 需个体化评估技术辅助自我管理项目的有效性。
核心结论
- 该数字健康项目未在12个月时显著改善糖尿病或糖尿病前期患者的HbA1c或体重。
研究设计与样本
- 随机平行分组两臂单盲优效性试验,在新西兰两个地区的初级保健机构开展。
- 干预组215人接受12个月移动设备和网络项目(健康教练、循证资源、同伴支持、目标追踪),对照组214人接受常规护理。
- 按基线HbA1c(糖尿病前期或糖尿病范围)和 ethnicity 分层随机(1:1分配),研究护士和生物统计师设盲。
主要发现
- 12个月时HbA1c在两组间无差异:糖尿病组平均差异-0.9 mmol/mol(95%CI -2.9, 1.1)(-0.1% [95%CI -0.3, 0.1]),糖尿病前期组0.0 mmol/mol(95%CI -0.9, 0.9)(0.0% [95%CI -0.1, 0.1])。
- 12个月时两组体重均轻度下降,组间无差异(平均差异-0.4 kg [95%CI -1.3, 0.5])。
临床怎么用
- 该特定数字健康项目不应被视为可常规改善糖尿病或糖尿病前期临床结局的有效工具。
- 鉴于技术辅助自我管理项目成本较高,临床采用前需个体化评估其有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this RCT was to evaluate the effectiveness of a digital health programme (BetaMe/Melon) vs usual care in improving the control of type 2 diabetes and prediabetes in a primary care population. METHODS: We conducted a randomised parallel-group two-arm single-blinded superiority trial in the primary care setting in two regions of New Zealand. Eligible participants were identified through Primary Health Organisations and participating practices. Eligibility criteria were as follows: age 18-75 years, HbA1c 41-70 mmol/mol (5.9-8.6%), not taking insulin, and daily access to the internet. BetaMe/Melon is a 12 month mobile-device and web-based programme with four components: health coaching; evidence-based resources; peer support; and goal tracking. Participants were randomised into the intervention or control arm (1:1 allocation) based upon baseline HbA1c (prediabetes or diabetes range), stratified by practice and ethnicity. Research nurses and the study biostatistician were blind to study arm. Primary outcomes of the study were changes in HbA1c and weight at 12 months, using an intention-to-treat analysis. RESULTS: Four hundred and twenty-nine individuals were recruited between 20 June 2017 and 11 May 2018 (n = 215 intervention arm, n = 214 control arm), most of whom were included in analyses of co-primary outcomes (n = 210/215, 97.7% and n = 213/214, 99.5%). HbA1c levels at 12 months did not differ between study arms: mean difference was -0.9 mmol/mol (95% CI -2.9, 1.1) (-0.1% [95% CI -0.3, 0.1]) for the diabetes group and was 0.0 mmol/mol (95% CI -0.9, 0.9) (0.0% [95% CI -0.1, 0.1]) for the prediabetes group. Weight reduced slightly at 12 months for participants in both study arms, with no difference between arms (mean difference -0.4 kg [95% CI -1.3, 0.5]). CONCLUSIONS/INTERPRETATION: This study did not demonstrate clinical effectiveness for this particular programme. Given their high costs, technology-assisted self-management programmes need to be individually assessed for their effectiveness in improving clinical outcomes for people with diabetes. TRIAL REGISTRATION: www.anzctr.org.au ACTRN12617000549325 (universal trial number U1111-1189-9094) FUNDING: This study was funded by the Health Research Council of New Zealand, the Ministry of Health New Zealand and the Healthier Lives National Science Challenge. Graphical abstract.
引用
- McLeod M, Stanley J, Signal V, et al. Impact of a comprehensive digital health programme on HbA1c and weight after 12 months for people with diabetes and prediabetes: a randomised controlled trial. Diabetologia. 2020. PMID: 32886192. doi:10.1007/s00125-020-05261-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。